74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Erasca Inc
Open
2.41 -2.03
Overview
Share price change
24h
Min
2.35
Max
2.48
Income | -2.9M -34M |
|---|---|
Profit margin | -768.16 |
Employees | 103 |
EBITDA | -2.5M -38M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +42.26% upside |
Next Earnings | 10 Nov 2025 |
|---|
Market Cap | 259M 678M |
|---|---|
Previous open | 4.44 |
Previous close | 2.41 |
Technical Score
By Trading Central
Confidence
Bearish Evidence
Erasca Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Erasca Inc Forecast
Price Target
By TipRanks
42.26% upside
12 Months Forecast
Average 3.4 USD 42.26%
High 6 USD
Low 1 USD
Based on 5 Wall Street analysts offering 12 month price targets forErasca Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Live chat